

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



## Summary of Financial Statements for the Nine Months Ended December 31, 2021 [IFRS] (Consolidated)



February 7, 2022

Company name: JMDC Inc.  
 Listing: Tokyo Stock Exchange  
 Stock code: 4483  
 URL: <https://www.jmdc.co.jp/eng/>  
 Representative: Yosuke Matsushima, President and CEO  
 Inquiries: Yuta Yamamoto, Vice President and CFO  
 TEL: +81-3-5733-5010  
 Scheduled date to file quarterly securities report: February 14, 2022  
 Scheduled date to commence dividend payments: —  
 Preparation of supplementary material on quarterly financial results: Yes  
 Holding of quarterly financial results presentation meeting: None

(Yen amounts are rounded down to millions, unless otherwise noted.)

### 1. Consolidated financial results for the first nine months of the fiscal year ending March 31, 2022 (from April 1, 2021 to December 31, 2021)

(1) Consolidated operating results (cumulative) (Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit	
Nine months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
December 31, 2021	15,679	35.1	3,417	41.0	3,408	41.6	2,279	44.4
December 31, 2020	11,606	34.1	2,424	63.7	2,406	67.2	1,578	62.3

	Profit attributable to owners of parent		Total comprehensive income		Basic earnings per share	Diluted earnings per share
Nine months ended	Millions of yen	%	Millions of yen	%	Yen	Yen
December 31, 2021	2,280	44.5	2,279	44.5	40.61	38.27
December 31, 2020	1,578	62.3	1,577	62.2	30.12	28.98

Reference: EBITDA Nine months ended December 31, 2021 ¥4,580 million [39.5%]  
 Nine months ended December 31, 2020 ¥3,284 million [45.9%]

Notes: 1. The Company conducted a 2-for-1 share split of its ordinary shares on October 1, 2020. Basic earnings per share and diluted earnings per share have been calculated assuming that the share split was conducted at the beginning of the previous fiscal year.

2. EBITDA: Operating profit + Depreciation and amortization ± Other income and/or expenses

### (2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent
As of	Millions of yen	Millions of yen	Millions of yen	%
December 31, 2021	60,393	30,154	30,154	49.9
March 31, 2021	58,264	28,250	28,250	48.5

Note: During the third quarter ended December 31, 2021, the Company finalized the provisional accounting treatment for business combinations. As a result, figures for the fiscal year ended March 31, 2021 reflect the finalization of the provisional accounting treatment.

## 2. Cash dividends

	Annual dividends				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2021	—	0.00	—	0.00	0.00
Fiscal year ending March 31, 2022	—	0.00	—		
Fiscal year ending March 31, 2022 (Forecast)				0.00	0.00

Note: Revisions to the forecast of cash dividends most recently announced: None

## 3. Consolidated earnings forecasts for the fiscal year ending March 31, 2022 (from April 1, 2021 to March 31, 2022)

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	
Fiscal year ending March 31, 2022	21,550	28.5	4,800	29.9	4,750	30.6	3,250	31.3	3,250	31.3	Yen 58.79

Note: Revisions to the earnings forecasts most recently announced: None

Reference: EBITDA Fiscal year ending March 31, 2022 (Forecast) ¥6,400 million [31.5%]

**\* Notes**

- (1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in scope of consolidation): None
- (2) Changes in accounting policies and changes in accounting estimates
- (i) Changes in accounting policies required by IFRS: None
- (ii) Changes in accounting policies due to other reasons: None
- (iii) Changes in accounting estimates: None

(3) Number of issued shares (ordinary shares)

(i) Total number of issued shares at end of the period (including treasury shares)

As of December 31, 2021	56,433,008 shares
As of March 31, 2021	55,935,808 shares

(ii) Number of treasury shares at end of the period

As of December 31, 2021	459 shares
As of March 31, 2021	366 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

For the nine months ended December 31, 2021	56,167,660 shares
For the nine months ended December 31, 2020	52,420,178 shares

Note: The Company conducted a 2-for-1 share split of its ordinary shares on October 1, 2020. The “average number of shares outstanding during the period” has been calculated assuming that the share split was conducted at the beginning of the previous fiscal year.

**\* Quarterly financial results reports are exempt from quarterly reviews conducted by certified public accountants or an audit corporation.**

**\* Proper use of earnings forecasts, and other special items**

Notes on forward-looking statements

The forward-looking statements, including earnings forecasts, contained in these materials are based on information currently available to the Company and on certain assumptions deemed to be reasonable by the Company. Actual business and other results may differ substantially due to various factors. For details regarding matters related to earnings forecasts, please refer to page 5 of the attached materials.

How to obtain supplementary documents on financial results

Supplementary documents on financial results are released via TDnet on the same day.

## Attached Material Index

1. Qualitative information regarding financial results for the nine months ended December 31, 2021 .....	2
(1) Explanation of operating results .....	2
(2) Explanation of financial position.....	4
(3) Explanation of consolidated earnings forecasts and other forward-looking statements.....	5
2. Condensed quarterly consolidated financial statements and significant notes thereto .....	6
(1) Condensed quarterly consolidated statement of financial position .....	6
(2) Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated statement of comprehensive income .....	7
(3) Condensed quarterly consolidated statement of changes in equity .....	9
(4) Condensed quarterly consolidated statement of cash flows .....	11
(5) Notes to condensed quarterly consolidated financial statements.....	12
Notes on going concern assumption.....	12
Segment information .....	12
Significant subsequent events.....	14

# 1. Qualitative information regarding financial results for the nine months ended December 31, 2021

## (1) Explanation of operating results

JMDC Inc. (the “Company”) is promoting the health of citizens, and delivering increased value of medical service providers and helping optimize their operations through gathering diverse data on the Japanese healthcare industry and thus benefiting society, with the aim of realizing a sustainable healthcare system by leveraging data and ICT.

In the Healthcare-Big Data segment, to promote the health services of health insurance associations, we provide analysis services for data held by health insurance associations as well as personal health record (PHR) services developed by the Company. We also provide services such as medical data analysis and medical factoring to medical institutions as well as medicine databases. Furthermore, we have created a database of anonymously processed information in the course of pursuing this business and are promoting scientific and industrial applications of this data.

In the Tele-medicine segment, we provide a matching service that connects medical institutions lacking a sufficient number of radiologists with contracted radiologists using a remote image interpretation system, as well as an ASP service that connects medical institutions with radiologists via the cloud to enable remote diagnostic imaging.

In the Dispensing Pharmacy Support segment, we develop and sell systems such as receipt computers and electronic medication history systems to health insurance pharmacies, and also conduct tests of our own systems as we operate our own dispensing pharmacies.

Operating results for the nine months ended December 31, 2021 are as follows.

(Operating results)

(Millions of yen)

Category	8th fiscal year Nine months ended December 31, 2020	9th fiscal year Nine months ended December 31, 2021	YoY change	
Revenue	11,606	15,679	4,073	35.1%
Operating profit	2,424	3,417	993	41.0%
EBITDA [Margin]	3,284 [28.3%]	4,580 [29.2%]	1,296	39.5%

(Segment results)

(Millions of yen)

Category		8th fiscal year Nine months ended December 31, 2020	9th fiscal year Nine months ended December 31, 2021	YoY change	
Healthcare-Big Data	Segment revenue	6,753	9,883	3,130	46.3%
	Segment profit [ratio]	2,316 [34.3%]	3,412 [34.5%]	1,096	47.3%
Tele-medicine	Segment revenue	3,000	3,370	370	12.3%
	Segment profit [ratio]	918 [30.6%]	1,200 [35.6%]	282	30.7%
Dispensing Pharmacy Support	Segment revenue	1,950	2,567	617	31.6%
	Segment profit [ratio]	241 [12.4%]	209 [8.1%]	(32)	(13.3)%
Adjustment	Segment revenue	(97)	(143)	(46)	—
	Segment profit	(192)	(242)	(50)	—
Total	Revenue	11,606	15,679	4,073	35.1%
	EBITDA [margin]	3,284 [28.3%]	4,580 [29.2%]	1,296	39.5%

Note: EBITDA is an objective indicator for judging the achievement of the JMDC Group’s management policies and strategies or management objectives. The JMDC Group uses EBITDA to measure the performance of each segment and believes that it is a useful and necessary measure to assess the Group’s performance more effectively. The formulas for calculating EBITDA and EBITDA margin are as follows.

- EBITDA: Operating profit + Depreciation and amortization ± Other income and/or expenses
- EBITDA margin: EBITDA / Revenue x 100

## Healthcare-Big Data

During the nine months ended December 31, 2021, various negative factors such as the curtailment of face-to-face sales due to the spread of the novel coronavirus disease (COVID-19) continued as in the previous fiscal year. However, the business continued to expand.

The number of contracted health insurance associations and the number of IDs issued for the PepUp health information platform developed by the Company continued to increase. Moreover, the Company is acquiring new health data in the electronic medical record (laboratory evidence) database that will be provided, with the total number of people exceeding 1,000,000.

Furthermore, the Company worked to expand services, such as by commencing the provision of “Doctorna,” which is a cloud service that quickly analyzes doctors’ academic activity, and the “health insurance finance estimate support service” for health insurance associations.

The business for healthcare providers continues to expand such as through the growing number of downloads for “Ishiyaku,” a medicine app for doctors, and the addition of ICM Co., Ltd. to the Group.

At the same time, in order to capture rapidly expanding business opportunities and accelerate future growth, we continue to make proactive up-front investments focused on personnel.

As a result, segment revenue for the nine months ended December 31, 2021 was ¥9,883 million and segment profit (segment EBITDA) was ¥3,412 million.

## Tele-medicine

During the nine months ended December 31, 2021, although the impact of a decrease in diagnostic imaging requests per medical institution due to the voluntary refraining from visiting hospitals as a result of the spread of COVID-19 continued, there was a gradual recovery year on year. Furthermore, the Company acquired the first pharmaceutical approval in Japan for an AI engine that detects pneumonia via chest X-rays (COVID-19), and continued to expand services in the area of remote image diagnostics, such as by providing and selling services related to “AI-RAD,” an artificial intelligence engine platform.

As a result, segment revenue for the nine months ended December 31, 2021 was ¥3,370 million and segment profit (segment EBITDA) was ¥1,200 million.

## Dispensing Pharmacy Support

During the nine months ended December 31, 2021, we worked to cultivate new customers while securing replacement demand from existing customers. Although the Group continued to be affected by a decline in sales at its own dispensing pharmacies and investment constraints at client dispensing pharmacies due to people refraining from visiting medical agencies, which will in turn reduce the number of times they visit dispensing pharmacies as a result of the spread of COVID-19, the scale of its operations expanded as a result of the launch of the next-generation “P-CUBEn” integrated electronic medication history receipt computer system, and the addition of a former competitor to the Group.

As a result, segment revenue for the nine months ended December 31, 2021 was ¥2,567 million and segment profit (segment EBITDA) was ¥209 million.

As a result of the above, for the nine months ended December 31, 2021, revenue increased to ¥15,679 million, operating profit to ¥3,417 million, and EBITDA to ¥4,580 million. Adjustments to reconcile EBITDA to operating profit are as follows.

## (Reconciliation of EBITDA to operating profit)

(Millions of yen)

	8th fiscal year Nine months ended December 31, 2020	9th fiscal year Nine months ended December 31, 2021
EBITDA	3,284	4,580
Depreciation and amortization	(848)	(1,179)
Other income	5	47
Other expenses	(17)	(31)
Operating profit	2,424	3,417

**(2) Explanation of financial position****(i) Assets, liabilities and equity****Assets**

Assets at the end of the third quarter under review were ¥60,393 million, an increase of ¥2,129 million compared with the end of the fiscal year ended March 31, 2021. Major changes included an increase of ¥4,859 million in goodwill as a result of the acquisition of new consolidated subsidiaries, etc., and an increase of ¥934 million in trade and other receivables as a result of business expansion. On the other hand, there was a decrease of ¥5,439 million in cash and cash equivalents as a result of repayments of borrowings, etc.

**Liabilities**

Liabilities at the end of the third quarter under review were ¥30,239 million, an increase of ¥226 million compared with the end of the fiscal year ended March 31, 2021. Major changes included a decrease of ¥2,512 million in borrowings under current liabilities as a result of repayments of borrowings and new borrowings, an increase of ¥989 million in borrowings under non-current liabilities, and an increase of ¥422 million in contract liabilities under current liabilities and an increase of ¥921 million in contract liabilities under non-current liabilities as a result of the addition of a former competitor to the Group and other factors in the Dispensing Pharmacy Support segment. Although contract liabilities had been included in other current liabilities up to the end of the fiscal year ended March 31, 2021, after a review due to the increased materiality, they are presented separately from the first quarter under review, and the consolidated financial statements for the previous fiscal year have been reclassified to reflect this change in presentation.

**Equity**

Equity at the end of the third quarter under review was ¥30,154 million, an increase of ¥1,904 million compared with the end of the fiscal year ended March 31, 2021. Major changes included the recording of ¥2,279 million in profit and increase (decrease) by business combination of negative ¥559 million.

**(ii) Cash flows**

Cash and cash equivalents (“cash”) at the end of the third quarter under review was ¥14,459 million, a decrease of ¥5,439 million compared with the end of the fiscal year ended March 31, 2021.

The respective cash flow positions for the nine months ended December 31, 2021, and the factors thereof are as follows.

**Cash flows from operating activities**

During the nine months ended December 31, 2021, profit before tax was ¥3,408 million, an increase of ¥1,002 million on a year-on-year basis. At the same time, as a result of recording of ¥(1,332) million in income taxes paid, net cash provided by operating activities was ¥1,883 million.

**Cash flows from investing activities**

Net cash used in investing activities was ¥5,268 million. This was primarily due to purchase of shares of subsidiaries resulting in change in scope of consolidation of ¥4,327 million and purchase of intangible assets of ¥597 million.

**Cash flows from financing activities**

Net cash used in financing activities was ¥2,055 million. This was primarily due to the recording of ¥2,622 million in repayments of short-term borrowings and ¥590 million in repayments of long-term borrowings, despite recording of ¥1,470 million in proceeds from long-term borrowings.

**(3) Explanation of consolidated earnings forecasts and other forward-looking statements**

The consolidated earnings forecasts are unchanged from the full-year earnings forecasts stated in the “Notice Concerning Differences Between Consolidated Earnings Forecasts and Actual Results for the Six Months Ended September 30, 2021, and Revision to Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2022” released on November 5, 2021.



## 2. Condensed quarterly consolidated financial statements and significant notes thereto

### (1) Condensed quarterly consolidated statement of financial position

(Millions of yen)

	As of March 31, 2021	As of December 31, 2021
<b>Assets</b>		
Current assets		
Cash and cash equivalents	19,898	14,459
Trade and other receivables	7,753	8,687
Other financial assets	152	255
Inventories	220	280
Other current assets	336	752
Total current assets	28,360	24,435
Non-current assets		
Property, plant and equipment	8,186	8,399
Goodwill	14,508	19,367
Intangible assets	4,904	5,091
Other financial assets	1,132	1,270
Deferred tax assets	975	1,650
Other non-current assets	196	177
Total non-current assets	29,903	35,957
Total assets	58,264	60,393
<b>Liabilities and equity</b>		
Liabilities		
Current liabilities		
Borrowings	3,288	776
Trade and other payables	5,842	5,945
Lease liabilities	621	669
Income taxes payable	768	576
Provisions	8	1
Contract liabilities	1,360	1,782
Other current liabilities	743	1,019
Total current liabilities	12,634	10,771
Non-current liabilities		
Borrowings	10,133	11,122
Lease liabilities	5,411	5,465
Retirement benefit liability	250	317
Provisions	190	274
Deferred tax liabilities	818	792
Contract liabilities	574	1,495
Total non-current liabilities	17,379	19,467
Total liabilities	30,013	30,239
Equity		
Share capital	8,971	9,070
Capital surplus	12,932	12,461
Treasury shares	(1)	(1)
Other components of equity	23	19
Retained earnings	6,323	8,605
Total equity attributable to owners of parent	28,250	30,154
Non-controlling interests	—	(0)
Total equity	28,250	30,154
Total liabilities and equity	58,264	60,393

**(2) Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated statement of comprehensive income**

Condensed quarterly consolidated statement of profit or loss

(Millions of yen)

	Nine months ended December 31, 2020	Nine months ended December 31, 2021
Revenue	11,606	15,679
Cost of sales	4,990	6,609
Gross profit	6,616	9,069
Selling, general and administrative expenses	4,180	5,668
Other income	5	47
Other expenses	17	31
Operating profit	2,424	3,417
Finance income	27	36
Finance costs	45	45
Profit before tax	2,406	3,408
Income tax expense	827	1,128
Profit	1,578	2,279
Profit attributable to		
Owners of parent	1,578	2,280
Non-controlling interests	—	(0)
Profit	1,578	2,279
Earnings per share		
Basic earnings per share (Yen)	30.12	40.61
Diluted earnings per share (Yen)	28.98	38.27

## Condensed quarterly consolidated statement of comprehensive income

(Millions of yen)

	Nine months ended December 31, 2020	Nine months ended December 31, 2021
Profit	1,578	2,279
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income	(1)	1
Total of items that will not be reclassified to profit or loss	(1)	1
Items that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	(0)	(1)
Total of items that may be reclassified to profit or loss	(0)	(1)
Other comprehensive income, net of tax	(1)	(0)
Comprehensive income	1,577	2,279
Comprehensive income attributable to		
Owners of parent	1,577	2,280
Non-controlling interests	—	(0)
Comprehensive income	1,577	2,279

**(3) Condensed quarterly consolidated statement of changes in equity**

Nine months ended December 31, 2020 (from April 1 to December 31, 2020)

(Millions of yen)

	Equity attributable to owners of parent					
	Share capital	Capital surplus	Treasury shares	Other components of equity		
				Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income	Share acquisition rights
Balance as of April 1, 2020	3,412	5,842	(0)	(0)	—	20
Profit	—	—	—	—	—	—
Other comprehensive income	—	—	—	(0)	(1)	—
Total comprehensive income	—	—	—	(0)	(1)	—
Issuance of share acquisition rights	—	—	—	—	—	8
Share-based remuneration transactions	—	—	—	—	—	8
Exercise of share acquisition rights	81	89	—	—	—	(4)
Issuance of new shares	5,357	5,324	—	—	—	—
Purchase of treasury shares	—	—	(1)	—	—	—
Increase (decrease) by business combination	—	4,584	—	—	—	—
Effect of business combinations under common control	—	(3,593)	—	—	—	—
Transfer to retained earnings	—	—	—	—	1	—
Total transactions with owners	5,439	6,405	(1)	—	1	11
Balance as of December 31, 2020	8,851	12,247	(1)	(0)	—	32

	Equity attributable to owners of parent			
	Other components of equity			Total
	Total	Retained earnings	Total	
Balance as of April 1, 2020	20	3,847	13,123	13,123
Profit	—	1,578	1,578	1,578
Other comprehensive income	(1)	—	(1)	(1)
Total comprehensive income	(1)	1,578	1,577	1,577
Issuance of share acquisition rights	8	—	8	8
Share-based remuneration transactions	8	—	8	8
Exercise of share acquisition rights	(4)	—	166	166
Issuance of new shares	—	—	10,682	10,682
Purchase of treasury shares	—	—	(1)	(1)
Increase (decrease) by business combination	—	—	4,584	4,584
Effect of business combinations under common control	—	—	(3,593)	(3,593)
Transfer to retained earnings	1	(1)	—	—
Total transactions with owners	12	(1)	11,854	11,854
Balance as of December 31, 2020	31	5,425	26,555	26,555

## Nine months ended December 31, 2021 (from April 1 to December 31, 2021)

(Millions of yen)

	Equity attributable to owners of parent					
	Share capital	Capital surplus	Treasury shares	Other components of equity		
				Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income	Share acquisition rights
Balance as of April 1, 2021	8,971	12,932	(1)	(2)	—	25
Profit	—	—	—	—	—	—
Other comprehensive income	—	—	—	(1)	1	—
Total comprehensive income	—	—	—	(1)	1	—
Issuance of share acquisition rights	—	—	—	—	—	1
Share-based remuneration transactions	—	—	—	—	—	0
Exercise of share acquisition rights	98	89	—	—	—	(4)
Forfeiture of share acquisition rights	—	—	—	—	—	(0)
Purchase of treasury shares	—	—	(0)	—	—	—
Increase (decrease) by business combination	—	(560)	—	—	—	—
Transfer to retained earnings	—	—	—	—	(1)	—
Total transactions with owners	98	(471)	(0)	—	(1)	(3)
Balance as of December 31, 2021	9,070	12,461	(1)	(3)	—	22

	Equity attributable to owners of parent				
	Other components of equity	Retained earnings	Total	Non-controlling interests	Total
	Total				
Balance as of April 1, 2021	23	6,323	28,250	—	28,250
Profit	—	2,280	2,280	(0)	2,279
Other comprehensive income	(0)	—	(0)	—	(0)
Total comprehensive income	(0)	2,280	2,280	(0)	2,279
Issuance of share acquisition rights	1	—	1	—	1
Share-based remuneration transactions	0	—	0	—	0
Exercise of share acquisition rights	(4)	—	182	—	182
Forfeiture of share acquisition rights	(0)	—	(0)	—	(0)
Purchase of treasury shares	—	—	(0)	—	(0)
Increase (decrease) by business combination	—	—	(560)	0	(559)
Transfer to retained earnings	(1)	1	—	—	—
Total transactions with owners	(4)	1	(376)	0	(376)
Balance as of December 31, 2021	19	8,605	30,154	(0)	30,154

**(4) Condensed quarterly consolidated statement of cash flows**

(Millions of yen)

	Nine months ended December 31, 2020	Nine months ended December 31, 2021
Cash flows from operating activities		
Profit before tax	2,406	3,408
Depreciation and amortization	848	1,179
Decrease (increase) in trade and other receivables	236	(740)
Decrease (increase) in inventories	(54)	(42)
Increase (decrease) in trade and other payables	(984)	(31)
Other	(417)	(550)
Subtotal	2,035	3,222
Interest and dividends received	27	36
Interest paid	(37)	(43)
Income taxes paid	(1,152)	(1,332)
Net cash provided by (used in) operating activities	873	1,883
Cash flows from investing activities		
Purchase of property, plant and equipment	(1,383)	(258)
Purchase of intangible assets	(626)	(597)
Payments for loans receivable	(2,622)	(10)
Purchase of investment securities	(223)	(53)
Proceeds from sale and redemption of investments	511	—
Proceeds from purchase of shares of subsidiaries resulting in change in scope of consolidation	361	—
Purchase of shares of subsidiaries resulting in change in scope of consolidation	(4,022)	(4,327)
Other	(138)	(21)
Net cash provided by (used in) investing activities	(8,143)	(5,268)
Cash flows from financing activities		
Proceeds from short-term borrowings	2,622	—
Repayments of short-term borrowings	(840)	(2,622)
Proceeds from long-term borrowings	6,394	1,470
Repayments of long-term borrowings	(487)	(590)
Repayments of lease liabilities	(384)	(496)
Proceeds from issuance of shares	10,714	—
Proceeds from exercise of share acquisition rights	159	182
Other	(18)	1
Net cash provided by (used in) financing activities	18,158	(2,055)
Net increase (decrease) in cash and cash equivalents	10,889	(5,439)
Cash and cash equivalents at beginning of period	7,692	19,898
Effect of exchange rate changes on cash and cash equivalents	0	0
Cash and cash equivalents at end of period	18,582	14,459

**(5) Notes to condensed quarterly consolidated financial statements****Notes on going concern assumption**

Not applicable.

**Segment information****(1) Overview of reportable segments**

The JMDC Group's reportable segments are components of the Group for which discrete financial information is available, and whose operating results are regularly reviewed by the Board of Directors to make decisions about managerial resources to be allocated to the segments and assess their performances. The JMDC Group consolidates multiple businesses based on the similarities in the nature of the services it provides and has three reportable segments: "Healthcare-Big Data," "Tele-medicine," and "Dispensing Pharmacy Support."

The businesses that comprise each reportable segment and the main services are as follows.

Reportable segments	Businesses that comprise reportable segments	Main services
Healthcare-Big Data	Business for industry Business for payers and individuals Business for healthcare providers	Development and provision of medical databases (receipts, pharmaceuticals, etc.) and analysis of medical big data
Tele-medicine	Tele-medicine business	Remote image interpretation matching service and ASP service for remote image interpretation system
Dispensing Pharmacy Support	Dispensing pharmacy support business	Development and sales of business systems for dispensing pharmacies

**(2) Information about reportable segments**

Revenue and operating results by reportable segments of the JMDC Group are as follows.

Intersegment revenues are based on negotiated transaction prices, taking into account market prices and production costs. Segment profits are EBITDA (Operating profit + Depreciation and amortization ± Other income/expenses).

Nine months ended December 31, 2020

(Millions of yen)

	Reportable segments				Adjustments (Note)	Consolidated
	Healthcare- Big Data	Tele-medicine	Dispensing Pharmacy Support	Total		
Revenue						
Revenue from external customers	6,728	3,000	1,876	11,606	—	11,606
Intersegment revenue	24	—	73	97	(97)	—
Total	6,753	3,000	1,950	11,704	(97)	11,606
Segment profit EBITDA	2,316	918	241	3,476	(192)	3,284

Note: Adjustments include elimination of intersegment transactions and corporate expenses.

## Nine months ended December 31, 2021

(Millions of yen)

	Reportable segments				Adjustments (Note)	Consolidated
	Healthcare- Big Data	Tele-medicine	Dispensing Pharmacy Support	Total		
Revenue						
Revenue from external customers	9,831	3,370	2,476	15,679	—	15,679
Intersegment revenue	52	—	90	143	(143)	—
Total	9,883	3,370	2,567	15,822	(143)	15,679
Segment profit EBITDA	3,412	1,200	209	4,823	(242)	4,580

Note: Adjustments include elimination of intersegment transactions and corporate expenses.

## A reconciliation of EBITDA to profit before tax is as follows.

(Millions of yen)

	Nine months ended December 31, 2020	Nine months ended December 31, 2021
EBITDA	3,284	4,580
Depreciation and amortization	(848)	(1,179)
Other income	5	47
Other expenses	(17)	(31)
Operating profit	2,424	3,417
Finance income	27	36
Finance costs	(45)	(45)
Profit before tax	2,406	3,408



**Significant subsequent events**

Not applicable.